US Patent

US10174061 — Carbidopa and L-dopa prodrugs and methods of use

Method of Use · Assigned to AbbVie Inc · Expires 2035-10-21 · 9y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating Parkinson's disease using carbidopa prodrugs and L-dopa prodrugs.

USPTO Abstract

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Drugs covered by this patent

foscarbidopa (FOSCARBIDOPA) · AbbVie GK

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4030`	—	foscarbidopa

Patent Metadata

Patent number: US10174061
Jurisdiction: US
Classification: Method of Use
Expires: 2035-10-21
Drug substance claim: No
Drug product claim: Yes
Assignee: AbbVie Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.